Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
69.27 ^USD	-2.93%		-3.29%	+10.30%

May. 22	Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing	MT
May. 14	Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	Mar. 04	CI
Vaxcyte Q4 Loss Widens	Feb. 27	MT
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	Jan. 29	CI
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise	Jan. 04	CI
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases	Dec. 04	CI
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket	Nov. 28	MT
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma	Nov. 27	MT
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults	Nov. 09	CI
Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Vaxcyte Says FDA Approves Investigational New Drug Application for Invasive Pneumococcal Disease Vaccine Candidate	23-10-19	MT
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults	23-10-19	CI
Vaxcyte, Lonza Sign Vaccine Manufacturing Agreement	23-10-16	MT
Lonza, Vaxcyte Expand Partnership With New Vaccine Manufacturing Facility	23-10-16	MT
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-08	AQ
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Vaxcyte, Inc. announces positive results from the VAX-24 Phase 2 study	23-04-17	CI
Vaxcyte, Inc. Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	23-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Highlights

Filters